Skip to content

Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy (Qol-Hypopara)

Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04053647
Enrollment
143
Registered
2019-08-12
Start date
2020-02-05
Completion date
2020-06-24
Last updated
2020-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoparathyroidism, Quality of Life

Brief summary

Persistent hypoparathyroidism is an underestimate but major complication of total thyroidectomy. The hypothesis of the investigators is that the mental health is impaired in hypoparathyroid patients compared with thyroidectomized patients without hypoparathyroidism. The investigators evaluated the quality of life using the SF-36 survey in comparison with a control population of patients thyroidectomized but free from this complication. The voice quality, the cardiovascular risk, the kidney function and the incidence of urinary lithiasis were also evaluated.

Detailed description

Persistent hypoparathyroidism is an underestimate but major complication of total thyroidectomy. In this retrospective, observational, multicentre study, the investigators evaluated the quality of life using the SF-36 survey in comparison with a control population of patients thyroidectomized but free from this complication. Patients in six centers in France (Angers, Le Mans, Limoges, Nancy, Nantes, la Pitié-Salpétrière) and in the association Hypoparathyroïdisme France were contacted by mail. The primary endpoint was the mental health. The physic and global quality of life scores were assessed as secondary endpoints. Medical and VHI surveys were also send to the patients. The voice quality, the cardiovascular risk, the kidney function and the incidence of urinary lithiasis were also evaluated.

Interventions

OTHERNon-interventional study

Non-interventional study

Sponsors

University Hospital, Angers
CollaboratorOTHER_GOV
Centre Hospitalier le Mans
CollaboratorOTHER
University Hospital, Limoges
CollaboratorOTHER
Central Hospital, Nancy, France
CollaboratorOTHER
Pitié-Salpêtrière Hospital
CollaboratorOTHER
Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients operated of total thyroidectomy * Patients suffering from persistent hypoparathyroidism defined as serum PTH inferior to 15 pg/mL 6 months after the surgery, requiring vitamin-calcic supplementation. * Age superior to 18 * Answering the survey

Exclusion criteria

* Pregnancy at the time of the study * Age inferior to 18 or adult under guardianship * Patients with vitamino-calcic supplementation without serum PTH measurement * Cause of hypoparathyroidism other than post-operatory.

Design outcomes

Primary

MeasureTime frameDescription
Mental healthThrough study completion, an average of 1 yearItems from mental quality of life score defined by the SF36 (Short Form 36) survey

Secondary

MeasureTime frameDescription
Global quality of life scoreThrough study completion, an average of 1 yearItems from the SF36 (Short Form 36) survey
Voice qualityThrough study completion, an average of 1 yearItems from the VHI (Voice Handicap Index) survey
Physical quality scoreThrough study completion, an average of 1 yearItems from the SF36 (Short Form 36) survey
Presence of urinary lithiasisThrough study completion, an average of 1 yearSerum creatinine and clearance dosage
Presence of cardiovascular complicationsThrough study completion, an average of 1 yearDefined as ischemic cardiopathy
Renal function qualityThrough study completion, an average of 1 yearSerum creatinine and clearance dosage

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026